Blinatumomab

Introduction Overview

Generic Name

blinatumomab

Brand Name

Blincyto

Dosage Form

injection for intravenous infusion

Drug Class

Bispecific T-cell engagers (BiTE)

Pharmacokinetics

Absorption

Blinatumomab is administered via continuous intravenous (IV) infusion, which bypasses the gastrointestinal tract and allows for direct introduction into systemic circulation. Due to its administration route, absorption variability associated with oral or other extravascular routes is not applicable. The continuous infusion allows a steady plasma concentration to be maintained, which is critical for its mechanism that requires sustained engagement of immune cells with malignant B cells.

Distribution

Blinatumomab, a bispecific monoclonal antibody construct, has a distribution profile characteristic of large protein therapeutics. It distributes primarily within the vascular and interstitial spaces. Volume of distribution is limited, corresponding largely to plasma and extracellular fluid volume due to its large molecular size. There is no significant crossing of the blood-brain barrier under normal conditions; however, distribution into cerebrospinal fluid may occur during intrathecal chemotherapy administered concomitantly to address CNS prophylaxis in acute lymphoblastic leukemia (ALL). Blinatumomab binds selectively to CD19-positive B cells and CD3-positive T cells, which can influence the apparent distribution as it forms synapses between effector and target cells.

Metabolism

Blinatumomab, as a biologic protein product, is metabolized primarily through proteolytic catabolism in the reticuloendothelial system and other protein-catabolizing pathways typical for monoclonal antibodies and related constructs. Unlike small molecule drugs, blinatumomab is not metabolized by cytochrome P450 enzymes; however, transient cytokine release induced by therapy can suppress CYP450 enzyme activity, potentially altering metabolism of concomitant medications dependent on this pathway. The half-life of blinatumomab is short compared to conventional antibodies, approximately 2 hours, which necessitates continuous infusion to maintain therapeutic plasma concentrations.

Elimination

Clearance of blinatumomab occurs predominantly via proteolytic degradation to small peptides and amino acids, without renal or hepatic excretion of intact drug. Its short half-life (~2 hours) results in rapid elimination when infusion is stopped. There is no significant renal or hepatic clearance pathway involvement. The pharmacokinetics of blinatumomab are not significantly affected by mild or moderate renal or hepatic impairment, but clinical data remain limited regarding severe impairment cases. Continuous intravenous infusion is required to maintain effective plasma levels given its rapid elimination.

Dosage Forms

Adults

Blincyto is supplied as a 35 mcg single-dose vial for reconstitution to be used as a sterile solution for intravenous infusion. The approved regimen involves continuous IV infusion delivered by a portable pump over 4-week cycles followed by 2-week treatment-free intervals. Dosage titration is conducted especially during initial treatment cycles to mitigate adverse effects such as cytokine release syndrome and neurotoxicity. Adults typically receive an induction dose of 9 mcg/day via continuous infusion for the first 7 days, then increased to 28 mcg/day for the remainder of the 28-day cycle. Consolidation cycles often use the 28 mcg/day dose continuously for 4 weeks followed by rest periods. Dosing adjustments are made based on clinical response and tolerability.

Adolescents

Pediatric patients aged 1 month and older are dosed based on body weight with a similar continuous infusion regimen as adults. Dosing starts at 5 mcg/m2/day continuous infusion for the first 7 days, escalating to 15 mcg/m2/day for the remainder of the cycle. The intended cycle length and rest periods align with adult protocols. Given the vulnerability of pediatric populations, especially infants, administration is generally under close clinical supervision initially. For children under 1 month of age, safety and efficacy have not been established, and use is not recommended.

Special Populations

In patients with renal or hepatic impairment, no formal dosing adjustments are currently recommended due to limited metabolism via these organs. However, close monitoring is advised due to potential side effects. For patients with neurological disorders, Down syndrome aged >10 years, or history of seizures, caution is paramount due to increased risk of neurotoxicity. Blincyto is contraindicated in pregnancy due to teratogenic risk and should not be used during breastfeeding. Elderly patients are treated similarly to adults but require close observation for adverse reactions. Immunocompromised patients and those with active infections require careful management, as Blincyto can lead to life-threatening infections. Dosage intensity and cycle number are determined individually by the treating physician based on response and toxicity.

Mechanism Of Action

Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct that simultaneously binds CD3 on cytotoxic T lymphocytes and CD19 on B cells, including malignant B-cell precursors in acute lymphoblastic leukemia (ALL). By bridging these two cell types, blinatumomab facilitates the formation of an immunologic synapse, which leads to T-cell activation independent of the major histocompatibility complex (MHC). Activated T cells then proliferate and induce apoptosis of CD19-expressing B cells through releasing cytolytic proteins such as perforin and granzymes. This targeted approach leverages the patient’s immune system to selectively kill leukemic B cells while sparing other cell types, thereby providing an immunotherapeutic modality distinct from traditional cytotoxic chemotherapy.

On a cellular level, blinatumomab engages and activates T cells with high potency even at low concentrations, inducing robust cytokine release and T-cell expansion. Unlike conventional monoclonal antibodies that elicit antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), blinatumomab directly recruits cytotoxic T cells and triggers their effector functions in the tumor microenvironment. This mechanism’s reliance on functional T cells explains the necessity for sustained intravenous infusion to maintain effective concentrations and preserve immune engagement during therapy cycles.

Biochemically, blinatumomab's unique structure comprises two single-chain variable fragments (scFvs) connected in tandem, conferring the dual specificity for CD3 and CD19. This design enables simultaneous binding without Fc region involvement, thereby minimizing Fc-mediated off-target effects and enabling rapid clearance from circulation. Clinical trials have demonstrated that blinatumomab achieves significant remissions in relapsed or refractory B-cell precursor ALL, including elimination of minimal residual disease, demonstrating clinical efficacy correlated to its mechanism of immune synapse formation and targeted cell lysis.

Comparatively, other bispecific antibodies or CAR-T therapies harness T-cell cytotoxicity but may differ in affinity, administration method, or persistence. Blinatumomab’s continuous infusion and short half-life contrast with long-acting CAR-T cell therapies, providing a controllable reversible treatment option with titratable dosing. Ongoing research explores combinational approaches and further optimization of binding affinities to enhance efficacy while managing toxicity profiles inherent in T-cell engaging therapies.

Pharmacological Actions

Selective binding to CD19 antigen expressed on B-cell precursors including malignant leukemic cells
Binding to CD3 receptors on T lymphocytes to activate cytotoxic T cells
Promotion of T-cell mediated targeted lysis of CD19-positive B cells through immune synapse formation
Induction of polyclonal T-cell proliferation and cytokine release resulting in enhanced antitumor immune response
Reduction of leukemic burden and elimination of minimal residual disease in B-cell precursor acute lymphoblastic leukemia
Lack of Fc region eliminates complement activation and Fc receptor-mediated effects, minimizing off-target cytotoxicity
Modulation of immune effector functions with a rapid onset due to continuous intravenous administration
No direct cytotoxic activity; action is dependent upon patient’s T-cell function
Transient suppression of cytochrome P450 enzymes via cytokine-mediated mechanisms, affecting metabolism of coadministered drugs
Ability to crosslink malignant and normal B cells to T cells resulting in selective immune-mediated destruction

Therapeutic Clinical Uses

Treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children aged 1 month and older
Therapy for relapsed or refractory B-cell precursor ALL after failure of prior treatments
Induction and consolidation therapy in Philadelphia chromosome-negative B-cell precursor ALL
Elimination of minimal residual disease (MRD) in patients achieving remission but with detectable leukemic cells
Immunotherapy alternative for patients ineligible for or refractory to conventional chemotherapy
Adjunct treatment to prevent central nervous system relapse with concomitant intrathecal chemotherapy
Use in combination with corticosteroids to manage infusion-related adverse reactions
Treatment in patients with high-risk cytogenetic subtypes of B-cell ALL
Option for maintaining remission post-hematopoietic stem cell transplantation in select cases

Side Or Adverse Effects

Fever (pyrexia) commonly associated with infusion
Infusion-related reactions including chills, rigors, and hypotension
Headache, including severe presentations associated with neurotoxicity
Infections due to immunosuppression, including bacterial and viral infections
Musculoskeletal pain such as muscle, joint, and bone pain
Hematologic toxicities including neutropenia, anemia, and thrombocytopenia
Gastrointestinal disturbances like diarrhea and nausea
Neurologic adverse effects: seizures, confusion, slurred speech, tremors, and encephalopathy
Cytokine release syndrome manifesting as fever, hypotension, malaise, and multi-organ dysfunction in severe cases
Tumor lysis syndrome causing metabolic abnormalities and renal impairment
Pancreatitis presenting with severe abdominal pain, possibly life-threatening
Low white blood cell counts increasing infection risk
Hypersensitivity reactions including rash, urticaria, and anaphylaxis
Fatigue and asthenia
Risk of seizure or loss of consciousness requiring activity restrictions

Precautions

Careful neurologic assessment before and during therapy due to risk of neurotoxicity
Monitor for signs of cytokine release syndrome especially during early infusion periods
Avoid use in patients with active uncontrolled infections
Use caution in patients with history of seizures or neurologic disorders, including those with Down syndrome
Close monitoring of blood counts needed due to risk of neutropenia and thrombocytopenia
Administer premedication with corticosteroids to mitigate infusion reactions
Ensure sterile technique and catheter care to reduce infection risk during prolonged IV infusion
Pregnancy testing and effective contraception required due to potential fetal harm
Avoid administration of live vaccines during and shortly after treatment
Regular liver function monitoring as hepatotoxicity may occur
Dose modifications or interruption may be required for adverse events
Ensure patients and caregivers are educated about signs and symptoms of severe adverse effects
Avoid in patients with hypersensitivity to blinatumomab or formulation excipients
Evaluate for tumor lysis syndrome risk and provide appropriate prophylaxis if indicated
Refrain from driving or hazardous activities during treatment due to risk of neurological side effects

Warnings

Black box warning for cytokine release syndrome which can be life-threatening
Severe neurologic toxicities including immune effector cell-associated neurotoxicity syndrome (ICANS)
Risk of serious and potentially fatal infections during treatment
Tumor lysis syndrome with rapid leukemic cell destruction leading to metabolic complications
Pancreatitis and severe abdominal pain requiring immediate evaluation
Neutropenia leading to life-threatening infections
Hypersensitivity reactions including anaphylaxis
Potential harm to fetus; contraindicated in pregnancy
Risk of seizures and loss of consciousness
Monitor for infusion-related reactions, some of which can be severe
Do not alter infusion pump settings to avoid dosing errors
Risk benefits must be considered carefully in patients with Down syndrome
Increased monitoring required during initial dosing and dose escalations
Close observation during the first 9 days of cycle 1 and first 2 days of cycle 2 when adverse risks are highest
Warnings related to use with concurrent immunosuppressants and narrow therapeutic index drugs

Contraindications

Known hypersensitivity to blinatumomab or any components of the formulation
Pregnancy due to potential teratogenicity and fetal harm
Patients with uncontrolled active infections
Concomitant use of live vaccines during and immediately after treatment
Patients unable to undergo continuous intravenous infusion or lacking access to appropriate infusion pump management
Severe neurologic conditions with current uncontrolled symptoms
Severe hepatic impairment without ability for close monitoring
Use in infants less than 1 month of age due to lack of safety data
Conditions predisposing to high risk of tumor lysis syndrome without adequate prophylaxis
Situations where immunosuppressive drug interactions cannot be safely managed

Drug Interactions

May transiently suppress cytochrome P450 enzymes via cytokine release, affecting metabolism of CYP450 substrates
Potential interaction with warfarin necessitating monitoring of INR and dose adjustments
Interactions with immunosuppressants metabolized by cytochrome P450 enzymes such as cyclosporin
No formal drug interaction studies conducted; caution advised with drugs having narrow therapeutic indices
Concurrent use with live vaccines contraindicated due to risk of infections
Potential additive immunosuppressive effects with concomitant chemotherapy agents
Possible increased risk of infusion reactions when combined with other immunotherapies
Close monitoring required when co-administered with drugs affecting the central nervous system due to overlapping neurotoxicity
No known interactions with common over-the-counter vitamins or herbal supplements, but caution advised
The cytokine-mediated effects may transiently affect pharmacokinetics of coadministered drugs

Preparations Of The Drug

Blincyto 35 mcg single-dose vial for reconstitution
Preservative-free sterile powder requiring reconstitution prior to dilution for infusion
Prepared as intravenous solution for continuous infusion using portable infusion pumps
Available infusion bag formulations supporting 24-hour, 48-hour, and 7-day infusion durations
Infusion bags may contain preservative-free or preservative-containing solutions; preservative-containing bags are not recommended for patients <22 kg
Packaging designed to maintain drug stability when refrigerated at 2°C to 8°C
Instructions for storage specify no freezing and protection within unopened packaging until use
Prepared infusion bags stable for 48 hours at room temperature for preservative-free preparations and up to 7 days for preservative-containing preparations
Supplied by Amgen, with detailed prescribing and administration guidelines included
Used in hospital, outpatient infusion centers, or at home under appropriate medical supervision